{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05112601","nct_id":"NCT05112601","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05112601. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.\n\nMAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.\n\nAdditionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial.","label":"Arm I (nivolumab and ipilimumab)","type":"EXPERIMENTAL"},{"description":"Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.\n\nMAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.\n\nAdditionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial.","label":"Arm II (nivolumab)","type":"ACTIVE_COMPARATOR"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2032-07-30","type":"ESTIMATED"},"conditions":["Endometrial Adenocarcinoma","Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Mucinous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Endometrioid Adenocarcinoma","Recurrent Endometrial Carcinoma"],"enrollment":{"count":81,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","type":"PROCEDURE"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Nivolumab","type":"BIOLOGICAL"}],"last_update":"2026-10-09","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2032-07-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS)","timeFrame":"From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization"}],"references":[],"start_date":{"date":"2022-06-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","url":"https://clinicaltrials.gov/study/NCT05112601"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05112601"}